Nasdaq · CIK 0001851484
CTOR CITIUS ONCOLOGY, INC.
Insider trading from SEC Form 4. Last filing Dec 22, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Signals
Open-market buys and sells at CITIUS ONCOLOGY, INC., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 43 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 19, 2025 | Carol Webb director | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 300,000 | Dec 22, 2025 |
| Sep 19, 2025 | Myron Z Holubiak Secretary | AGrant or award Common Stock | +850,000 | $0.00 | $0 | 850,000 | Dec 22, 2025 |
| Sep 19, 2025 | Myron Czuczman Chief Medical Officer | AGrant or award Common Stock | +825,000 | $0.00 | $0 | 825,000 | Dec 22, 2025 |
| Sep 19, 2025 | Leonard L Mazur Chief Executive Officer | AGrant or award Common Stock | +1,700,000 | $0.00 | $0 | 1,700,000 | Dec 22, 2025 |
| Sep 19, 2025 | Robert Joseph Smith director | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 300,000 | Dec 22, 2025 |
| Sep 19, 2025 | Dennis M McGrath director | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 300,000 | Dec 22, 2025 |
| Sep 19, 2025 | Joel David Mayersohn director | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 321,228 | Dec 22, 2025 |
| Sep 19, 2025 | Suren G Dutia director | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 300,000 | Dec 22, 2025 |
| Sep 19, 2025 | Eugene Myron Holuka director | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 300,000 | Dec 22, 2025 |
| Sep 19, 2025 | Jaime Bartushak Chief Financial Officer | AGrant or award Common Stock | +825,000 | $0.00 | $0 | 825,000 | Dec 22, 2025 |
| Sep 19, 2025 | Carol Webb director | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 300,000 | Dec 1, 2025 |
| Sep 19, 2025 | Joel David Mayersohn director | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 321,228 | Dec 1, 2025 |
| Sep 19, 2025 | Dennis M McGrath director | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 300,000 | Dec 1, 2025 |
| Sep 19, 2025 | Myron Z Holubiak Secretary | AGrant or award Common Stock | +850,000 | $0.00 | $0 | 850,000 | Dec 1, 2025 |
| Sep 19, 2025 | Robert Joseph Smith director | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 300,000 | Dec 1, 2025 |
| Sep 19, 2025 | Leonard L Mazur Chief Executive Officer | AGrant or award Common Stock | +1,700,000 | $0.00 | $0 | 1,700,000 | Dec 1, 2025 |
| Sep 19, 2025 | Suren G Dutia director | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 300,000 | Dec 1, 2025 |
| Sep 19, 2025 | Myron Czuczman Chief Medical Officer | AGrant or award Common Stock | +825,000 | $0.00 | $0 | 825,000 | Dec 1, 2025 |
| Sep 19, 2025 | Jaime Bartushak Chief Financial Officer | AGrant or award Common Stock | +825,000 | $0.00 | $0 | 825,000 | Dec 1, 2025 |
| Sep 19, 2025 | Eugene Myron Holuka director | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 300,000 | Dec 1, 2025 |
| Sep 19, 2025 | Joel David Mayersohn director | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 321,228 | Sep 23, 2025 |
| Sep 19, 2025 | Myron Z Holubiak Secretary | AGrant or award Common Stock | +850,000 | $0.00 | $0 | 850,000 | Sep 23, 2025 |
| Sep 19, 2025 | Suren G Dutia director | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 300,000 | Sep 23, 2025 |
| Sep 19, 2025 | Robert Joseph Smith director | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 300,000 | Sep 23, 2025 |
| Sep 19, 2025 | Leonard L Mazur Chief Executive Officer | AGrant or award Common Stock | +1,700,000 | $0.00 | $0 | 1,700,000 | Sep 23, 2025 |
| Sep 19, 2025 | Carol Webb director | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 300,000 | Sep 23, 2025 |
| Sep 19, 2025 | Dennis M McGrath director | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 300,000 | Sep 23, 2025 |
| Sep 19, 2025 | Myron Czuczman Chief Medical Officer | AGrant or award Common Stock | +825,000 | $0.00 | $0 | 825,000 | Sep 23, 2025 |
| Sep 19, 2025 | Eugene Myron Holuka director | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 300,000 | Sep 23, 2025 |
| Sep 19, 2025 | Jaime Bartushak Chief Financial Officer | AGrant or award Common Stock | +825,000 | $0.00 | $0 | 825,000 | Sep 23, 2025 |
| Sep 19, 2025 | Myron Z Holubiak Secretary | AGrant or award Common Stockindirect: See footnote | +100,000 | $0.00 | $0 | 100,000 | Sep 23, 2025 |
| Jul 28, 2025 | Joel David Mayersohn director | JOther Common Stock | +21,228 | $0.00 | $0 | 21,228 | Aug 7, 2025 |
| Dec 12, 2024 | Joel David Mayersohn director | AGrant or award Stock Option (Right to Buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Dec 16, 2024 |
| Dec 12, 2024 | Eugene Myron Holuka director | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Dec 16, 2024 |
| Dec 12, 2024 | Myron Z Holubiak Secretary | AGrant or award Stock Option (Right to Buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Dec 16, 2024 |
| Dec 12, 2024 | Robert Joseph Smith director | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Dec 16, 2024 |
| Dec 12, 2024 | Carol Webb director | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Dec 16, 2024 |
| Dec 12, 2024 | Suren G Dutia director | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Dec 16, 2024 |
| Dec 12, 2024 | Dennis M McGrath director | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Dec 16, 2024 |
| Dec 12, 2024 | Leonard L Mazur Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +800,000 | $0.00 | $0 | 800,000 | Dec 16, 2024 |
| Dec 12, 2024 | Myron Czuczman Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +400,000 | $0.00 | $0 | 400,000 | Dec 16, 2024 |
| Dec 12, 2024 | Jaime Bartushak Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +400,000 | $0.00 | $0 | 400,000 | Dec 16, 2024 |
| Dec 12, 2024 | Myron Z Holubiak Secretary | AGrant or award Stock Option (Right to Buy)derivativeindirect: See footnote | +50,000 | $0.00 | $0 | 50,000 | Dec 16, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Jaime BartushakChief Financial Officer
- Myron CzuczmanChief Medical Officer
- Suren G Dutiadirector
- Myron Z HolubiakSecretary
- Eugene Myron Holukadirector
- Dennis M McGrathdirector, cfo, president, officer
- Joel David Mayersohndirector
- Leonard L MazurChief Executive Officer
- Robert Joseph Smithdirector
- Carol Webbdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.